Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhejiang Center for Disease Control and Prevention · Sinovac Biotech · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,507
total citations
- FWCI
- 33.95
- Percentile
- 100%
- References
- 28
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Tolerability
- Placebo
- Vaccination
- Cohort
- Clinical trial
- Internal medicine
- Randomized controlled trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.